| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 | EFFECT |
| 04 Nov 2026 | S-3 |
| 04 Nov 2026 | 424B5 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 |
| 11 Jun 2026 |
Form 4: George Simeon, Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Schmid John P., Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Lappe Rodney W, Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Gover Justin D., Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Shapiro David, Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Berger Heather A., Director
Granted 30,000 Stock Option (right to buy) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Design Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstand... |
| 09 Jun 2026 | SCHEDULE 13G |
| 18 May 2026 |
8-K: Other Events
On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”). |
| 15 May 2026 | SCHEDULE 13G/A |
Loading...